Expression Analysis of BDNF Gene and BDNF-AS Long Noncoding RNA in Whole Blood Samples of Multiple Sclerosis Patients: Not Always a Negative Correlation between Them
-
Vajiheh Gharzi
,
Maziar Gangi
,
Arezou Sayad
,
Mehrdokht Mazdeh
,
Shahram Arsang-Jang
,
Mohammad Taheri
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS), in which axonal damage is a deteriorative factor. Brain-Derived Neurotrophic Factor (BDNF) is described as a neuronal-survival gene, also capable of exerting pleiotropic effects on the immune cells. Here, we aimed to investigate expression levels of BDNF and its antisense RNA, BDNF-AS, in Iranian MS patients. Our case-control study was based on collecting 50 whole blood samples of relapsing-remitting MS patients and 50 healthy controls. Then, expression analysis of BDNF and BDNF-AS was performed by Real-time quantitative PCR. We found a strong and positive correlation between BDNF and BDNF-AS in MS patients. This is while no significant difference in BDNF and BDNF-AS expression levels was seen between MS patients and controls (p>0.05). A significant and strong positive correlation was found between the expression levels of BDNF-AS and BDNF (r=0.785, p<0.0001). Further, significant positive moderate correlations of BDNF and BDNF-AS with other lncRNAs (GSTT1-AS1 and IFNG-AS1) and genes (TNF and IFNG) were revealed (p<0.0001). Additionally, there was no correlation between the BDNF and BDNF-AS expressions and disease duration, age at onset, and Expanded Disability Status Scale of Kurtzke (EDSS) (p>0.05). BDNF and BDNF-AS expression levels revealed insignificant discrepancies in patients and controls. We found a strong and positive correlation between BDNF and BDNF-AS in MS patients, which is, based on previous studies, a quit novel finding and can be further discussed by future works to unravel its possible application in MS. We suggest evaluation of different leukocytes subsets separately along with large cohort studies comprising a higher number of individuals from different ages to unravel the effects of other possible aspects.
style='mso-element:field-begin'>
style='mso-spacerun:yes'> ADDIN EN.REFLIST
field-separator'>1. Kallaur AP, Oliveira SR, Alfieri DF, Flauzino T, Lopes J, Pereira WLdCJ, et al. Cytokine profile in patients with progressive multiple sclerosis and its association with disease progression and disability. Molecular neurobiology. 2017;54(4):2950-60.
2. Kallaur AP, Reiche EMV, Oliveira SR, Pereira WLdCJ, Alfieri DF, Flauzino T, et al. Genetic, immune-inflammatory, and oxidative stress biomarkers as predictors for disability and disease progression in multiple sclerosis. Molecular neurobiology. 2017;54(1):31-44.
3. Ebers GC. Environmental factors and multiple sclerosis. The Lancet Neurology. 2008;7(3):268-77.
4. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nature Reviews Neurology. 2014;10(4):225-38.
5. De Santi L, Cantalupo L, Tassi M, Raspadori D, Cioni C, Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis. Journal of the neurological sciences. 2009;277(1):65-70.
6. Hammarberg H, Lidman O, Lundberg C, Eltayeb S, Gielen A, Muhallab S, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. Journal of Neuroscience. 2000;20(14):5283-91.
7. Zhu W, Acosta C, MacNeil BJ, Klonisch T, Cortes C, Doupe M, et al. Spinal cord brain derived neurotrophic factor (BDNF) responsive cells in an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS): implications in myelin repair. Res Immunol Int J. 2014;2014.
8. KhorshidAhmad T, Acosta C, Cortes C, Lakowski TM, Gangadaran S, Namaka M. Transcriptional regulation of brain-derived neurotrophic factor (BDNF) by methyl CpG binding protein 2 (MeCP2): a novel mechanism for re-myelination and/or myelin repair involved in the treatment of multiple sclerosis (MS). Molecular neurobiology. 2016;53(2):1092-107.
9. Yoshimura S, Ochi H, Isobe N, Matsushita T, Motomura K, Matsuoka T, et al. Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. Multiple Sclerosis Journal. 2010;16(10):1178-88.
10. Linker RA, Lee D-H, Demir S, Wiese S, Kruse N, Siglienti I, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain. 2010;133(8):2248-63.
11. Eftekharian MM, Ghafouri-Fard S, Soudyab M, Omrani MD, Rahimi M, Sayad A, et al. Expression Analysis of Long Non-coding RNAs in the Blood of Multiple Sclerosis Patients. Journal of Molecular Neuroscience. 2017;63(3-4):333-41.
12. Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer biology & medicine. 2015;12(1):1.
13. Zhang Y, Yan L, Cao Y, Kong G, Lin C. Long noncoding RNA BDNF-AS protects local anesthetic induced neurotoxicity in dorsal root ganglion neurons. Biomedicine & Pharmacotherapy. 2016;80:207-12.
14. Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nature biotechnology. 2012;30(5):453-9.
15. Sayad A, Ghafouri-Fard S, Omrani MD, Noroozi R, Taheri M. Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients. Neurological Sciences. 2017;38(6):1093-9.
16. Taheri M, Ghafouri-Fard S, Solgi G, Sayad A, Mazdeh M, Omrani MD. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex. Cytokine. 2017;96:138-43.
17. Liguori M, Fera F, Patitucci A, Manna I, Condino F, Valentino P, et al. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing–remitting multiple sclerosis. Brain research. 2009;1256:123-8.
18. Patanella AK, Zinno M, Quaranta D, Nociti V, Frisullo G, Gainotti G, et al. Correlations between peripheral blood mononuclear cell production of BDNF, TNF‐alpha, IL‐6, IL‐10 and cognitive performances in multiple sclerosis patients. Journal of neuroscience research. 2010;88(5):1106-12.
19. Dinoff A, Herrmann N, Swardfager W, Liu CS, Sherman C, Chan S, et al. The Effect of exercise training on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF): a meta-analysis. PloS one. 2016;11(9):e0163037.
20. Barouch R, Appel E, Kazimirsky G, Brodie C. Macrophages express neurotrophins and neurotrophin receptors: regulation of nitric oxide production by NT-3. Journal of neuroimmunology. 2001;112(1):72-7.
21. Ziemssen T, Kümpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate‐specific T‐helper 1‐and 2‐type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain. 2002;125(11):2381-91.
22. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiology of aging. 2005;26(1):115-23.
23. De Santi L, Annunziata P, Sessa E, Bramanti P. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. Journal of the neurological sciences. 2009;287(1):17-26.
24. Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins. Multiple Sclerosis Journal. 2007;13(3):313-31.
25. Lindquist S, Hassinger S, Lindquist JA, Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Multiple Sclerosis Journal. 2011;17(7):851-66.
26. McTigue DM, Horner PJ, Stokes BT, Gage FH. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. Journal of Neuroscience. 1998;18(14):5354-65.
27. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Journal of neuroimmunology. 2000;107(2):161-6.
28. Ikeda O, Murakami M, Ino H, Yamazaki M, Koda M, Nakayama C, et al. Effects of brain-derived neurotrophic factor (BDNF) on compression-induced spinal cord injury: BDNF attenuates down-regulation of superoxide dismutase expression and promotes up-regulation of myelin basic protein expression. Journal of Neuropathology & Experimental Neurology. 2002;61(2):142-53.
29. Shang W, Yang Y, Zhang J, Wu Q. Long noncoding RNA BDNF-AS is a potential biomarker and regulates cancer development in human retinoblastoma. Biochemical and Biophysical Research Communications. 2017.
30. Xu L, Zhang Z, Xie T, Zhang X, Dai T. Inhibition of BDNF-AS Provides Neuroprotection for Retinal Ganglion Cells against Ischemic Injury. PloS one. 2016;11(12):e0164941.
31. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298-307.
32. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. Journal of neurology. 2005;252(5):v3-v9.
33. Bjartmar C, Wujek J, Trapp B. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. Journal of the neurological sciences. 2003;206(2):165-71.
34. Frota ERC, Rodrigues DH, Donadi EA, Brum DG, Maciel DRK, Teixeira AL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neuroscience letters. 2009;460(2):130-2.
35. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. Journal of neuroimmunology. 2002;132(1):180-8.
36. Caggiula M, Batocchi A, Frisullo G, Angelucci F, Patanella A, Sancricca C, et al. Neurotrophic Factors and Clinical Recovery in Relapsing‐Remitting Multiple Sclerosis. Scandinavian journal of immunology. 2005;62(2):176-82.
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-ansi-language:
EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>
style='mso-element:field-end'>
| Files | ||
| Issue | Vol 17, No 6 (2018) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijaai.v17i6.619 | |
| Keywords | ||
| Brain-derived neurotrophic factor Brain-derived neurotrophic factor antisense RNA Gene expression Multiple sclerosis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
